Epoch 18: TARGETED PROTEIN DEGRADATION
Advantages, Disadvantages, Competitive Landscape, Future Directions
Welcome to the 84 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,181 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:
Hello Avatar! Welcome back for another week of biotech analysis. This week we will be shifting to a scientific focus with a deep dive into one of the hottest areas in biotech - targeted protein degradation (TPD). If you are not aware of this technology we will quickly bring you up to speed on what it is and why it has everyone excited. We will summarize the advantages and disadvantages of the technology before going into a full competitive landscape analysis covering not only today’s focus but what people are working on in the next innovation wave - quite exciting, we promise!
We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.
Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts. This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences. We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction. Be sure to SUBSCRIBE to not miss.
Enough shilling for the day, lots to cover this week, let's get started!
TARGETED PROTEIN DEGRADERS
Today we are going to take a deep dive into one of the hottest areas in biotech - targeted protein degradation (TPG) and "molecular glues". Readers new to the substack are encouraged to also have a read of our previous write up on this topic from over one year ago: Week 52 - Drugging the UnDruggable
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.